Transcript
Slackbot Advertiser (0:00)
AI is incredible. It can teach you how to fry an egg and even write a poem, pirate style, but it knows nothing about your work. Slackbot is different. It doesn't just know the facts, it knows your schedule. It can turn a brainstorm into a brief. And it doesn't need to be taught, because Slackbot isn't just another AI. It's AI that knows your work as well as you do. Visit slack.com meetslackbot to learn more.
Ann Barry (0:31)
Amazon is building a supercenter, while Walmart is rolling out drones. We survey the latest in the grocery wars. Delta stock hits turbulence on today's earnings, but can premium seating get the airline's bottom line back on course? And two titans syncing up for groundbreaking medical research. That's Nvidia and Eli Lilly. We break down this week's big announcement for Tuesday, January 13th. It's Brew Markets Daily and I'm Ann Ber Foreign. More market details to come, but first, it's a massive week for healthcare, with San Francisco hosting the industry's great and it's good for the annual J.P. morgan Healthcare Conference. It's a packed event at which public companies in biotech, pharmaceuticals, health insurance and more unleash waves of announcements on their latest developments, from gene editing technology updates to personalized medicine breakthroughs to of course, the latest in obesity treatments. Now this area was an absolute hive of activity at the end of 2025, with Pfizer spending $7 billion plus contingent payments to acquire the young clinical stage biopharmaceutical company Msera back in November. Now it was a big price tag to help Pfizer push harder and faster into oral weight loss solutions, outbidding the Danish pharma heavyweight Novo Nord Disc, who in turn by the way launched the first ever GLP1 pill for weight loss in America just a few weeks ago on January 4th. Now Novo's WeGovy Pill has helped to push the company stock up 16% already in the short year to date. Well, another GLP1 giant, Eli Lilly, maker of Zepbound and Manjaro, isn't sitting on the sidelines wading into the news cycle with a headline grabber or three of its own. Recently affectionately referred to as Lilly with Ticker lly, it's the first healthcare company to hit a trillion dollar market cap, a milestone it reached in November. Now Lilly has seen its share price up over 35% for the past six months, and its 2026 is off to a busy start. Just last week, Lilly announced it's buying NASDAQ listed Ventix Biosciences, which is developing therapies to treat cardiometabolic, neurodegenerative and inflammatory disorders. In addition to that $1.2 billion buyout, Lilly announced an upsized partnership with Nimbus Therapeutics, which uses AI enhanced computational chemistry to develop oral treatments for obesity and other diseases. A push again away from injections into oral treatments. And for the third big announcement for January, and as a reminder, we are only 13 days into this month. Eli Lilly this week unveiled a new initiative with a partner that's even bigger than Lilly is, and that is Nvidia. Together, the chip giant and the drug giant will invest up to a billion dollars over five years in a new co innovation lab. And work on the San Francisco located lab is expected to begin as early as March 31st. So under this construct, Nvidia's engineers will physically work alongside Lilly's experts in biology to build AI models designed to accelerate medicine development. Now, it's not the first time that Nvidia and Lilly have partnered together. Back in October, Lilly announced its AI supercomputer for drug discovery built using Nvidia's Blackwell products. The this new co innovation lab will expand on that using Nvidia's next gen Rubin systems. And the partners are going to go beyond drug discovery to other parts of the medicine making process. They plan to explore ways to apply AI across clinical development, manufacturing and commercial operations. And by the way, they're going to be using all the AI things. Multimodal models, agentic AI robotics, digital twins. It's like all the buzzwords actually coming together for this particular use case. Well, we're going to keep on watching. There is a ton of jargon in both the pharma and tech sectors, but when you bust through it, these are really exciting developments. With real world applications coming on up, Amazon is delivering something new. A supercenter retail store that's even bigger than a Walmart. But first, a word from our sponsor, Public John. Have you ever used AI for investing?
